Enzalutamide

Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator[1][2].

Product Specifications

CAS Number

[915087-33-1]

Product Name Alternative

MDV3100

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Androgen Receptor; Autophagy

Type

Reference compound

Related Pathways

Autophagy; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Enzalutamide.html

Purity

99.97

Solubility

DMSO : ≥ 50 mg/mL

Smiles

S=C(N(C(C1(C)C)=O)C2=CC=C(C#N)C(C(F)(F)F)=C2)N1C3=CC(F)=C(C(NC)=O)C=C3

Molecular Formula

C21H16F4N4O2S

Molecular Weight

464.44

Precautions

H315, H319, H335

References & Citations

[1]Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790.|[2]Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375 (9724), 1437-1446.|[3]Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73 (12) :1291-305.|[4]Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38 (11) :2076-82.